Travere Therapeutics, Inc.
TVTX
$33.99
-$1.20-3.41%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 162.11% | 111.49% | 97.54% | 65.98% | 69.56% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 162.11% | 111.49% | 97.54% | 65.98% | 69.56% |
| Cost of Revenue | 0.32% | -9.77% | 1.26% | 0.48% | -13.86% |
| Gross Profit | 1,061.10% | 2,894.11% | 415.85% | 152.81% | 138.71% |
| SG&A Expenses | 31.75% | 17.66% | 13.41% | 9.30% | -3.22% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 17.66% | 4.90% | 8.04% | 4.87% | -8.29% |
| Operating Income | 144.50% | 81.13% | 42.15% | 28.37% | 39.49% |
| Income Before Tax | 146.89% | 81.69% | 69.66% | 31.84% | 38.54% |
| Income Tax Expenses | 109.52% | -76.47% | -79.58% | -205.88% | -800.00% |
| Earnings from Continuing Operations | 146.95% | 81.69% | 69.68% | 31.97% | 38.65% |
| Earnings from Discontinued Operations | -- | -- | -- | 100.25% | -100.02% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 146.90% | 81.88% | 69.70% | 33.17% | -136.36% |
| EBIT | 144.50% | 81.13% | 42.15% | 28.37% | 39.49% |
| EBITDA | 190.92% | 102.41% | 53.25% | 35.59% | 44.78% |
| EPS Basic | 140.88% | 84.22% | 73.55% | 38.50% | -135.67% |
| Normalized Basic EPS | 140.97% | 83.90% | 48.86% | 29.70% | 39.85% |
| EPS Diluted | 139.08% | 84.22% | 73.55% | 38.50% | -135.67% |
| Normalized Diluted EPS | 135.62% | 83.90% | 48.86% | 29.70% | 39.85% |
| Average Basic Shares Outstanding | 14.72% | 14.77% | 14.54% | 8.67% | 1.93% |
| Average Diluted Shares Outstanding | 31.94% | 14.77% | 14.54% | 8.67% | 1.93% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |